Fujifilm plans $20M U.S. facility for burgeoning interest in stem cell treatments  

Stem cells
Fujifilm will build a stem cell manufacturing facility in Madison, Wisconsin. (FDA)

A host of companies are developing regenerative treatments that lean on stem cells. Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own efforts but also as a CDMO. 

The company said today that its Fujifilm Cellular Dynamics Inc. (FDCI) subsidiary will invest about $21 million to build a facility in Madison, Wisconsin, to “industrialize” induced pluripotent stem cell technologies for its pipeline of regenerative drugs and to manufacture iPS cells for others. It expects the facility to be ready by March 2020.

“To meet the growing demand for FCDI’s iPS cell platform, the state-of-the-art production facility will have a flexible cell culturing design to serve production requirements of both industrial quantities of cells, and small, diverse batches,” Seimi Satake, FCDI CEO, said in a statement. “By combining Fujifilm’s experience gleaned from the intricate process of manufacturing photographic film along with FCDI’s knowledge of cell reprogramming, genetic engineering and cell differentiation, the facility is poised to address the complex manufacturing processes of cell therapies.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Fujifilm pointed to its investment in and work with Australian biotech Cynata Therapeutics as an indication of its experience. The Melbourne-based company is using a technology called Cymerus to manufacture mesenchymal stem cells to treat cytokine release syndrome, a severe immune reaction in some patients taking CAR-T treatments. Additionally, it said FCDI is already manufacturing iPS cell products for research by public institutions, pharma companies and academia.

RELATED: Novo picks up California plant from Asterias as it moves stem cell work forward

A couple of other stem cell manufacturing facilities were announced toward the end of last year. Novo Nordisk, which is investigating stem cell treatments that might eventually cure Type 1 diabetes, is building out a facility in Fremont, California, that it has leased from stem cell biotech Asterias Biotherapeutics. Orchard Therapeutics is investing up to $90 million to build a manufacturing facility for its gene therapies program, also in Fremont.

Suggested Articles

The FDA has handed down its decision against Sanofi and Lexicon's Zynquista.

Analysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie's upadacitinib leads the pack.

The new Alcon shares will be listed on the Swiss Exchange and the New York Stock Exchange on April 9 under the ticker “ALC.”